Researchers at ETH Zurich have refined the famous CRISPR-Cas method. Now, for the very first time, it is possible to modify dozens, if not hundreds, of genes in a cell simultaneously.
Everyone’s talking about CRISPR-Cas. This biotechnological method offers a relatively quick and easy way to manipulate single genes in cells, meaning they can be precisely deleted, replaced or modified. Furthermore, in recent years, researchers have also been using technologies based on CRISPR-Cas to systematically increase or decrease the activity of individual genes. The corresponding methods have become the worldwide standard within a very short time, both in basic biological research and in applied fields such as plant breeding.
To date, for the most part, researchers could modify only one gene at a time using the method. On occasion, they managed two or three in one go; in one particular case, they were able to edit seven genes simultaneously. Now, Professor Randall Platt and his team at the Department of Biosystems Science and Engineering at ETH Zurich in Basel have developed a process that – as they demonstrated in experiments – can modify 25 target sites within genes in a cell at once. As if that were not enough, this number can be increased still further, to dozens or even hundreds of genes, as Platt points out. At any rate, the method offers enormous potential for biomedical research and biotechnology. “Thanks to this new tool, we and other scientists can now achieve what we could only dream of doing in the past.”
Targeted, large-scale cell reprogramming
Genes and proteins in cells interact in many different ways. The resulting networks comprising dozens of genes ensure an organism’s cellular diversity. For example, they are responsible for differentiating progenitor cells to neuronal cells and immune cells. “Our method enables us, for the first time, to systematically modify entire gene networks in a single step,” Platt says.
Moreover, it paves the way for complex, large-scale cell programming. It can be used to increase the activity of certain genes, while reducing that of others. The timing of this change in activity can also be precisely controlled.
This is of interest for basic research, for example in investigating why various types of cells behave differently or for the study of complex genetic disorders. It will also prove useful for cell replacement therapy, which involves replacing damaged with healthy cells. In this case, researchers can use the method to convert stem cells into differentiated cells, such as neuronal cells or insulin-producing beta cells, or vice versa, to produce stem cells from differentiated skin cells.
The dual function of the Cas enzyme
The CRISPR-Cas method requires an enzyme known as a Cas and a small RNA molecule. Its sequence of nucleobases serves as an “address label”, directing the enzyme with utmost precision to its designated site of action on the chromosomes. ETH scientists have created a plasmid, or a circular DNA molecule, that stores the blueprint of the Cas enzyme and numerous RNA address molecules, arranged in sequences: in other words, a longer address list. In their experiments, the researchers inserted this plasmid into human cells, thereby demonstrating that several genes can be modified and regulated simultaneously.
For the new technique, the scientists did not use the Cas9 enzyme that has featured in most CRISPR-Cas methods to date, but the related Cas12a enzyme. Not only can it edit genes, it can also cut the long “RNA address list” into individual “address labels” at the same time. Furthermore, Cas12a can handle shorter RNA address molecules than Cas9. “The shorter these addressing sequences are, the more of them we can fit onto a plasmid,” Platt says.
Learn more: Revolutionising the CRISPR method
The Latest on: CRISPR
[google_news title=”” keyword=”CRISPR” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: CRISPR
- ChatGPT for genomes: introducing a CRISPR-designing generative AIon May 17, 2024 at 11:39 am
Molecular engineer Patrick Hsu and Arc Institute colleagues trained an AI model on vast troves of biological data from 80,000 genomes of bacteria and archaea. #STATBreakthrough ...
- Is CRISPR Therapeutics Stock a Buy?on May 17, 2024 at 6:31 am
Although CRISPR Therapeutics will only receive 40% of the profits associated with Casgevy because of its agreement with Vertex Pharmaceuticals, the deal was well worth it. There is no way a mid-cap ...
- Mystery CRISPR unlocked: A new ally against antibiotic resistance?on May 16, 2024 at 11:54 am
CRISPR-Cas systems have revolutionized biotechnology by offering ways to edit genes like a pair of programmable scissors. In nature, bacteria use these systems to fight off deadly viruses. A recent ...
- Is CRISPR Stock Going to $95? 1 Wall Street Analyst Thinks So.on May 15, 2024 at 8:11 am
CRISPR Therapeutics (NASDAQ: CRSP) closed last week down 8.5% after reporting first-quarter "earnings" results that looked a lot more like losses. Lacking a big milestone payment like the one in Q1 ...
- CRISPR can treat common form of inherited blindness, early data hinton May 15, 2024 at 7:33 am
In a small trial, some people with inherited vision loss experienced improvements in their sight after being treated with CRISPR.
- Excision’s CRISPR-Based HIV Treatment Fails to Show Curative Potential in Early Studyon May 13, 2024 at 8:32 am
Results from a Phase I study presented Friday at the ASGCT 2024 annual meeting showed that despite a good safety profile, Excision BioTherapeutics’ HIV gene editor failed to suppress viral activity.
- CRISPR restores some vision to blind patients in clinical trialon May 13, 2024 at 1:55 am
CRISPR gene-editing has improved the vision of patients with an inherited form of blindness, according to results of a Phase 1/2 clinical trial. The results not only give new hope to patients with the ...
- CRISPR edits fail to cure HIV patients in early teston May 10, 2024 at 10:13 am
Excision BioTherapeutics reported Friday that an early trial failed to cure HIV patients, but the company plans to try again with a more efficient editing treatment.
- CRISPR-based gene editing treatment shows promise for rare eye disorderon May 9, 2024 at 8:08 am
Researchers at Oregon Health & Science University used an experimental CRISPR-based gene editing treatment in participants with a rare eye disorder that causes low vision and blindness. The results ...
- CRISPR therapy restores some vision to people with blindnesson May 8, 2024 at 5:00 pm
People with an inherited condition that causes vision loss in childhood had vision improvements after treatment to replace a mutated gene.
via Bing News